{"id":55246,"date":"2023-03-28T12:05:10","date_gmt":"2023-03-28T10:05:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/"},"modified":"2023-03-28T12:05:10","modified_gmt":"2023-03-28T10:05:10","slug":"avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/","title":{"rendered":"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division"},"content":{"rendered":"<div>\n<p>LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer of its Therapeutics Division.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/5\/Avacta_%28RGB%29_reg.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg\"><\/a><\/p>\n<p>\nIn her new role, Karen will be responsible for supporting the research and development functions across Avacta\u2019s Therapeutics Division, with her focus exclusively on creating maximum value for the Group\u2019s stakeholders. Latest clinical data for the Company\u2019s lead pre|CISION\u2122 programme, AVA6000, has demonstrated its ongoing very favourable safety profile and tumour-targeting potential, with patients in cohort 4 of the dose-escalation phase I trial experiencing a marked reduction in the incidence and severity of the typical toxicities associated with standard doxorubicin chemotherapy administration<sup>1<\/sup>.\n<\/p>\n<p>\nKaren joins Avacta with over 30 years\u2019 experience managing complex global B2C organisations; designing, planning and implementing strategies, plans and procedures, with a focus on operational excellence, promotion of company culture and vision, and continuous improvement. Within the last 15 years, she has undertaken senior positions predominantly within the healthcare and life sciences sectors, including Vice President for Talent at Astellas Pharma. Karen has grown private equity-backed businesses, with a focus on value creation through expansion, partnerships, and acquisitions, and also has significant experience of successfully delivering business transformation and integration, globally, in competitive, consumer-focused environments.\n<\/p>\n<p>\n<b>Dr Alastair Smith, Chief Executive Officer of Avacta Group plc, commented: <\/b><i>\u201cKaren\u2019s industry experience is extensive, we\u2019re really pleased to welcome her as Chief Operating Officer of our Therapeutics Division. Karen\u2019s guidance to strategise and prioritise Avacta\u2019s operational requirements, establish achievable performance measures and set comprehensive goals for the Therapeutics\u2019 business growth and success will benefit the division greatly and help shape its future strategy as we continue our mission to transform treatment outcomes for cancer patients.\u201d<\/i>\n<\/p>\n<p>\n<b>Karen Harrison, Chief Operating Officer, Therapeutics, Avacta Group plc, added: <\/b><i>\u201cAvacta is a pioneer of next-generation cancer therapies, and I\u2019m delighted to join and support the Company\u2019s vision to revolutionise the treatability of solid tumours. The Therapeutics Division is at such a pivotal stage, with the latest clinical data for AVA6000 confirming the tumour-targeting potential of our pre|CISION<\/i>\u2122<i> technology. I look forward to the opportunity to help drive our promising platforms further in the clinic and ultimately improve the lives of patients suffering from cancer.\u201d<\/i>\n<\/p>\n<p>\n1. Press release (17<sup>th<\/sup> January, 2023): <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Favacta.com%2Favacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study%2F&amp;esheet=53369190&amp;newsitemid=20230328005510&amp;lan=en-US&amp;anchor=Avacta+Announces+Successful+Completion+of+Fourth+Dose+Escalation+in+AVA6000+Phase+1+Clinical+Study&amp;index=1&amp;md5=d95cba3c016dbacb3ef6afb5ed6c0f4e\" rel=\"nofollow noopener\" shape=\"rect\">Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study<\/a>\n<\/p>\n<p class=\"bwalignc\">\n<b>ENDS<\/b>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Zyme Communications <\/b>(Trade and Regional Media)<br \/>\n<br \/>Lily Jeffery Tel: +44 (0)7891 477 378<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x6c;&#105;ly&#x2e;&#x6a;&#101;&#102;f&#x65;&#x72;&#x79;&#64;zy&#x6d;&#x65;&#99;&#111;m&#x6d;&#x75;&#x6e;&#105;ca&#x74;&#x69;&#111;&#110;s&#x2e;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6c;&#105;l&#x79;&#46;j&#x65;&#x66;&#102;&#x65;&#x72;&#121;&#64;&#x7a;&#121;m&#x65;&#x63;&#111;&#x6d;&#x6d;&#117;n&#x69;&#99;a&#x74;&#x69;&#111;&#x6e;&#x73;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer of its Therapeutics Division. In her new role, Karen will be responsible for supporting the research and development functions across Avacta\u2019s Therapeutics Division, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55246","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer of its Therapeutics Division. In her new role, Karen will be responsible for supporting the research and development functions across Avacta\u2019s Therapeutics Division, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T10:05:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division\",\"datePublished\":\"2023-03-28T10:05:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/\"},\"wordCount\":430,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005510\\\/en\\\/1749069\\\/21\\\/Avacta_%28RGB%29_reg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/\",\"name\":\"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005510\\\/en\\\/1749069\\\/21\\\/Avacta_%28RGB%29_reg.jpg\",\"datePublished\":\"2023-03-28T10:05:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005510\\\/en\\\/1749069\\\/21\\\/Avacta_%28RGB%29_reg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005510\\\/en\\\/1749069\\\/21\\\/Avacta_%28RGB%29_reg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/","og_locale":"en_US","og_type":"article","og_title":"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division - Pharma Trend","og_description":"LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer of its Therapeutics Division. In her new role, Karen will be responsible for supporting the research and development functions across Avacta\u2019s Therapeutics Division, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T10:05:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division","datePublished":"2023-03-28T10:05:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/"},"wordCount":430,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/","url":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/","name":"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg","datePublished":"2023-03-28T10:05:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230328005510\/en\/1749069\/21\/Avacta_%28RGB%29_reg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avacta-appoints-karen-harrison-as-chief-operating-officer-for-therapeutics-division\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55246"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55246\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}